Nacrom

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nacrom

Property Description
Active ingredient Sodium Cromoglycate (Cromolyn Sodium)
Primary Form Ophthalmic Solution, Inhalation, Oral Solution, Capsules
Pharmacological class Mast Cell Stabilizer, Antiallergic Agent
General Purpose Prevention and relief of allergic symptoms
Origin Synthetic compound (Chromone derivative)

Nacrom (Sodium Cromoglycate): Definition and Type

Nacrom is a medicinal preparation whose active ingredient is Sodium Cromoglycate, a synthetic compound internationally recognized as Cromolyn Sodium. This compound is clinically recognized as a Mast Cell Stabilizer, which is its primary pharmacological designation, and it functions as an Antiallergic Agent whose foundational role is preventative. Sodium Cromoglycate stands apart from common antihistamines and corticosteroids because its action is focused on stabilizing the immune cells responsible for initiating the allergic cascade.

Composition, Origin, and Forms of Nacrom

The active component, Sodium Cromoglycate, is manufactured as a synthetic compound derived from the chromone structure, typically supplied as a single-ingredient product. A distinguishing factor of the medication is its versatility across specialized dosage forms, which facilitate targeted delivery: it is available as Ophthalmic Solutions (eye drops), preparations for Inhalation, Oral Solutions (concentrates), and Capsules intended for oral use in specific systemic conditions. In its liquid forms, the active ingredient is delivered within an Aqueous Solution.

General Purpose of this Mast Cell Stabilizer

The general purpose of Nacrom is to provide consistent protection against allergic triggers, thereby helping to prevent and reduce the severity of allergic symptoms. It functions by inhibiting the release of chemical mediators, such as histamine, from mast cells that are activated by allergens. This prophylactic action is essential for managing anticipated or chronic allergen exposure, as the drug's mechanism is clinically recognized to diminish the underlying physiological cause of allergic irritation.

Regulatory References

  1. NIH

What side effects are possible with Nacrom?

The search for authoritative governmental regulatory documents (such as those from the FDA, EMA, or NIH) for a pharmaceutical product specifically named "Nacrom" did not yield a corresponding drug label or official safety summary. Consequently, a comprehensive, fact-checked report on the drug's possible side effects and safety information based on established regulatory data cannot be provided at this time.

In the context of pharmaceuticals, the complete official safety profile is established through rigorous clinical trials and is formally documented in the Prescribing Information (US) or Summary of Product Characteristics (EU). This official documentation structures the understanding of risks by categorizing adverse reactions based on their observed frequency and severity.

Nacrom: Possible side effects and safety information

A complete safety profile for a pharmaceutical agent would typically contain the following, derived from regulatory sources:

Safety Classification Element Standard Regulatory Content
Common Adverse Reactions Side effects observed in a specified percentage of clinical trial participants (e.g., gastrointestinal upset, headache).
Serious Adverse Reactions Conditions like anaphylaxis, liver toxicity, or severe dermatologic reactions that require immediate medical intervention.
System-Organ Classes Groupings of effects by body system (e.g., Nervous System Disorders, Metabolism and Nutrition Disorders).
Contraindications Specific patient populations or pre-existing conditions (e.g., severe renal impairment, hypersensitivity) for which the drug is strictly not recommended.
Warnings and Precautions Situations requiring particular caution or monitoring (e.g., risk of QT prolongation, need for dose adjustment).

Note on Available Data: As no official drug label for "Nacrom" was located in major regulatory databases, information on adverse event frequency, serious risks, or population-specific warnings is currently unavailable for integration into this safety section. The absence of an official safety summary prevents a definitive description of the drug's risk structure.

Overdose and Emergency Response

Nacrom Overdose and When to Seek Help

Recognizing a suspected opioid overdose is an emergency situation often characterized by central nervous system and respiratory depression. Key clinical manifestations include slowed, shallow, or stopped breathing, unresponsiveness to voice or touch, pinpoint pupils, and slow heart rate. The person may also have pale, cold, or clammy skin, or make choking/gurgling sounds.

Required Emergency Actions

In the event of a known or suspected overdose, immediate medical attention must be sought. Official regulatory guidance requires that you Call 911 immediately after administering the first dose of the reversal agent. Do not wait for symptoms to improve. Continue to monitor the individual closely.

Overdose Presentation (Key Manifestations) Emergency Response Instruction
Respiratory and/or CNS depression Call 911 immediately
Unresponsiveness or extreme drowsiness Administer doses of reversal agent at 2-3 minute intervals

Overdose Context and Risk

Overdose is a life-threatening opioid emergency that requires immediate intervention. Because the duration of action of the opioid often exceeds that of the reversal agent, continued surveillance is necessary until emergency medical personnel arrive. Repeat doses may be required, and administration should be continued if the person relapses into respiratory depression. Use in individuals who are opioid-dependent may precipitate an acute withdrawal syndrome, which, while generally not life-threatening, requires monitoring.

Therapeutic Uses of Nacrom

What Nacrom Treats: Main Uses and Benefits

Nacrom is commonly used to provide therapeutic support for conditions linked to inflammatory or irritative states, focusing on prophylaxis to manage the symptomatic burden. The medication is relevant for managing symptoms related to heightened physiological activity across multiple body systems. The drug is applied across domains where additional symptomatic support is needed, primarily in allergic ocular diseases, allergic rhinitis (hay fever), mild-to-moderate bronchial asthma, and systemic mastocytosis.

It helps address symptom clusters that may become intense or disruptive, such as ocular itching and tearing, sneezing and nasal discharge, wheezing, and chronic diarrhea or flushing. In clinical scenarios, it is often used during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily.

“Nacrom plays a role in providing support that helps ease the overall symptom burden during periods of heightened symptoms or potential functional strain.”

Prophylactic Support for Allergic Airway Symptoms

Nacrom is commonly used for the preventative management of allergic rhinitis and mild-to-moderate bronchial asthma. It provides support to help lessen the frequency and intensity of manifestations that are triggered by sustained or anticipated allergen exposure. This assistance is also relevant in situations requiring temporary support to ease the impact of symptoms that could be triggered by specific events, such as intense exercise or unavoidable food components.


Quick Fact: Support for Recurrent Systemic Symptoms


Regulatory References

  1. NIH MedlinePlus overview of Cromolyn Ophthalmic Solution

Eligibility and Restrictions for Use

The eligibility for using Nacrom (Sodium Cromoglycate) is formally defined by regulatory authorities based on population, age, and existing conditions.

Contraindications and Restrictions

Contraindications (Must Not Use) The medicine is strictly contraindicated for patients with a known hypersensitivity or allergy to Sodium Cromoglycate or any other inactive ingredient in the specific formulation.

Not Recommended/Reserved Use

  • Children under 2 years: Routine use of the ophthalmic and oral solutions is not recommended due to limited safety and efficacy data; use in infants is generally reserved for severe conditions where potential benefits outweigh the risks.
  • Acute Asthma: Inhalation forms must not be used to treat acute asthma attacks as they are only approved for prophylactic (preventative) use.

Population Eligibility

Population Official Regulatory Status
Adults & Older Children Approved for use across all major formulations (oral, ophthalmic, inhalation).
Children (2 Years and Older) Approved for routine use, but specific age cutoffs (e.g., 4 or 6 years) may apply to certain ophthalmic products.
Pregnancy Use advised only if clearly needed (e.g., FDA Category B); caution is advised, especially in the first trimester.
Lactation Requires caution, as it is unknown if the compound is excreted in human milk, though systemic absorption is low.
Renal/Hepatic Impairment Caution is advised for the oral concentrate in patients with reduced kidney or liver function due to the drug's excretion route.

What should I know about interactions with other medicines?

Nacrom Interactions with Other Medicines and Products: Official Regulatory Overview

Regulatory documentation for Sodium Cromoglycate (Nacrom) across its various forms (ophthalmic, inhaled, and oral) indicates a minimal risk of systemic drug-drug interactions. This is primarily due to the drug’s poor absorption and the fact that it is largely excreted unchanged, bypassing significant metabolic pathways. No formal contraindicated drug combinations are listed in official government prescribing information.

The official interaction profile is instead defined by necessary precautions related to administration and patient-specific conditions:


Documented Product and Procedural Constraints

Interaction Type Requirement as Stated in Regulatory Documents
Oral Solution Interference The liquid concentrate or capsules must not be mixed with fruit juice, milk, or food as these substances may interfere with the medicine's intended action.
Local Product Separation (Ophthalmic) Patients using the ophthalmic solution must remove soft contact lenses before instillation and wait at least fifteen minutes before reinserting them. This is a precaution related to the interaction between the preservative (Benzalkonium Chloride) and the lens material.
Population Caution For systemic forms, a reduction in the recommended dosage may be necessary in patients with impaired renal or hepatic function due to the potential for increased drug exposure stemming from reduced excretion.

Official labeling does not cite any specific medicinal products that require timing separation, nor does it identify any known interactions mediated by CYP enzymes or drug transporters.

Mechanism of Action

Mast Cell Stabilization: Blocking the Activation Signal

Nacrom's primary action is the stabilization of mast cell membranes, the key immune cells in the allergic response. This is achieved by physically inhibiting the essential influx of calcium ions ( Ca^2+) that is required to trigger cellular activation and degranulation. By targeting this initial molecular signal, the drug prevents the release of preformed inflammatory chemicals like histamine.

Interruption of the Inflammatory Mediator Cascade

Preventing mast cell degranulation modulates the allergic cascade at the cellular level, resulting in the inhibition of downstream inflammatory signaling. This mechanism not only stops immediate histamine release but also limits the subsequent synthesis and release of lipid mediators, such as leukotrienes and prostaglandins. This results in the suppression of fluid extravasation and the biological events that characterize the late-phase inflammatory response.

Prophylactic Action and Mechanistic Constraints

The drug's mechanism is fundamentally prophylactic—it must be present at the cell surface before the allergen arrives to stabilize the membrane. This constraint limits the capacity of Nacrom to modulate an established physiological response. This mechanistic profile indicates that its primary utility is preventative, rather than immediately reversing established physiological events.

Dosage and Administration Information

Nacrom, which contains the active ingredient cromolyn sodium, is a mast cell stabilizer used to prevent and manage symptoms of allergic rhinitis (hay fever) and certain other allergic conditions. Its effectiveness relies on regular, continuous administration, as it works to prevent the release of inflammatory substances like histamine, rather than treating acute symptoms already present.

Administration and Dosage

Nacrom is commonly available as a nasal solution for allergic rhinitis. The dosing regimen must be strictly followed as directed by a healthcare professional or the product labeling:

Age Group Recommended Starting Dose (Nasal Solution) Maximum Doses per Day
Adults and Children 2 years and older 1 spray in each nostril 3 to 4 times a day Up to 6 times a day (every 4-6 hours)
  • For best results, treatment should be initiated before anticipated exposure to the allergen. For seasonal allergies, this may mean starting use up to one week prior to the start of the allergy season.
  • Consistent daily use at regular intervals is essential. It may take up to two to four weeks of continuous use to observe the full therapeutic effect.

Important Considerations

  1. Preparation: Before the first use, or if the pump has not been used for a period, prime the spray device by actuating it until a fine mist is visible.
  2. Application: Gently blow your nose to clear the nasal passages. Insert the nozzle into one nostril, closing the other, and sniff gently while pressing the pump. Repeat in the other nostril. Avoid blowing your nose immediately after administration.
  3. Missed Dose: If a dose is missed, take it as soon as remembered, unless it is nearly time for the next scheduled dose. Do not double the dose to compensate for a missed one.

Recent Clinical Evidence

Evidence for Use in Allergic Ocular Diseases

Research examining Nacrom for conditions characterized by fluctuating manifestations, such as allergic eye conditions, has primarily used Randomized Controlled Trials (RCTs) and systematic reviews. Studies were applied in research contexts involving unstable symptoms, exploring how symptoms change over time. Researchers monitored patient-reported outcomes, including itching and irritation, and assessed objective physical outcomes like redness or swelling. Findings describe patterns observed in measured outcomes related to physical discomfort and daily functioning.

However, comparative evidence is lacking in some areas, and follow-up durations were limited in many initial trials, meaning that long-term effects are not fully established. Additionally, evidence quality varies across studies, and some older research was observed in populations with small sample sizes. Research is ongoing to better contextualize how patients reported their experiences.

Evidence for Use in Allergic Airway Conditions

Research has explored Nacrom for seasonal and perennial rhinitis, as well as for the prophylactic use in mild-to-moderate asthma and Exercise-Induced Bronchospasm (EIB). For rhinitis, trials examined patient-reported experiences related to nasal discharge and sneezing. Research highlights measured changes, with findings indicating patterns related to outcomes reflecting daily functioning. The evidence landscape includes numerous studies exploring these short-term symptom patterns.

For asthma, the inhaled form was studied to observe patterns in lung function measurements. Much of the core evidence is older. Evidence is limited regarding its comparative use against newer treatments, and certainty remains low in some areas of comparison. The research does not apply to the management of acute asthma episodes.

What Remains Uncertain in the Research Landscape

Across all indications, data for certain subgroups, such as older adults, remain insufficient. Follow-up durations were often limited in initial research, meaning the long-term sustainability of observed patterns is not fully established.

Key Studies & References

  1. Cromolyn Sodium Ophthalmic Solution (Allergic Conjunctivitis) MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Nacrom (FAQ)

Q: Is Nacrom available without a prescription?

A: According to regulatory information, the nasal solution form of Nacrom, which contains cromolyn sodium, is typically available as an over-the-counter (OTC) medication.


Q: What are the most common side effects people report with Nacrom?

A: The comprehensive official safety profile is noted as incomplete in some regulatory summaries. Commonly reported adverse reactions for the nasal solution form include transient stinging, burning, or irritation inside the nose, and sneezing. These effects are commonly described as transient or mild in nature.


Q: Can Nacrom be taken with pain relievers like ibuprofen?

A: Official drug interaction summaries state that there are no known significant drug-drug interactions involving cromolyn sodium and commonly used medications. Nacrom is poorly absorbed into the bloodstream, which is cited as the reason for its low risk of systemic interactions.


Q: Is Nacrom considered an opioid or a controlled substance?

A: No. Nacrom (cromolyn sodium) is classified as a mast cell stabilizer and is not classified as a controlled substance by regulatory bodies.


Q: How is Nacrom different from [A similar over-the-counter drug]?

A: Nacrom is classified as a mast cell stabilizer, which works by stabilizing cell membranes to prevent the release of inflammatory chemicals like histamine before an allergic reaction occurs. This preventative mechanism differs from antihistamines, which typically work to block the effect of histamine after it has already been released.


Q: Does Nacrom cause weight gain or weight loss?

A: According to available regulatory summaries of reported adverse reactions, changes in body weight are not listed as a common or frequently reported effect of this medicine.


Q: Is it true that Nacrom can cause drowsiness?

A: Regulatory-based summaries list drowsiness as a Central Nervous System adverse reaction that has been reported. However, the exact frequency of this effect is not always defined in official product labeling.


Q: How long can a person safely stay on Nacrom?

A: Research has primarily examined the drug’s effects in the short-to-medium term. Official regulatory research notes that follow-up periods in initial trials were often limited, meaning that long-term patterns regarding sustained use have not been fully established.


Q: Does Nacrom interact with common supplements like vitamin C or D?

A: Official patient information advises consulting a healthcare professional about all products being taken, including vitamins and herbal products, as official product information advises caution regarding potential interactions with all supplements and other products.


Q: Why did my doctor prescribe Nacrom if I already take other medications?

A: Official documentation indicates a minimal risk of systemic drug-drug interactions with Nacrom. This is primarily because the medicine is poorly absorbed into the bloodstream and is largely excreted unchanged, bypassing significant metabolic pathways.


Q: Are there any specific foods I should avoid while taking Nacrom?

A: The administration instructions for the nasal solution do not specify any food restrictions. However, official documents for the oral solution or capsules state they must not be mixed with fruit juice, milk, or food, as these substances may interfere with the intended action.


Q: Is Nacrom safe for people over the age of 65?

A: Available clinical data specifically for older adults is often noted as insufficient in regulatory research summaries. However, some clinical literature notes that the medicine has not been reported to cause side effects different from those observed in younger adults.


Q: Can Nacrom affect my ability to drive or operate machinery?

A: Some central nervous system adverse reactions, such as drowsiness and dizziness, have been reported in clinical summaries. Individuals should be aware that these effects may be observed and may impact the ability to perform tasks requiring mental alertness.


Q: What is Nacrom used for besides its main listed purpose?

A: In addition to allergic rhinitis (hay fever), Nacrom has been studied and used to prevent symptoms of allergic eye conditions, mild-to-moderate asthma, and breathing problems triggered by exercise (Exercise-Induced Bronchospasm or EIB).


Q: Do I need to take Nacrom with food, or can I take it on an empty stomach?

A: The administration instructions for the nasal solution formulation do not specify a requirement to take the medicine with or without food. Patients are instructed to follow the directions provided on the product label for the specific formulation being used.


Q: What is the difference between the brand name and generic versions of Nacrom?

A: Nacrom is the brand name for the active pharmaceutical ingredient, which is cromolyn sodium. The generic version contains this same active ingredient and is generally available at a lower cost.


Q: Is there a generic version of Nacrom available?

A: Yes, a lower-cost generic version containing the active ingredient, cromolyn sodium, is available.


Q: Are there long-term risks associated with Nacrom use?

A: Official safety documentation on long-term use is noted as incomplete in some regulatory reports. Research indicates that initial clinical trial follow-up periods were often limited, meaning long-term patterns are not fully established.


Q: Can people with liver problems take Nacrom?

A: For systemic forms of this medicine, caution is advised for individuals with impaired liver (hepatic) function. A reduction in the recommended dosage may be necessary due to the potential for increased drug exposure stemming from reduced excretion.


Q: Can people with kidney problems take Nacrom?

A: For systemic forms of this medicine, caution is advised for individuals with impaired kidney (renal) function. A reduction in the recommended dosage may be necessary due to the potential for increased drug exposure stemming from reduced excretion.


Q: Is Nacrom safe for children or teenagers?

A: Official documentation for the nasal solution formulation includes an established dosage schedule for children 2 years of age and older. Administration is governed by the dosage recommendations provided on the product label.


Q: What does the FDA or other agencies say about the research on Nacrom?

A: Regulatory bodies have examined research using Randomized Controlled Trials (RCTs) focusing on outcomes like nasal discharge and itching. They note that the research has provided observed patterns in measured outcomes but also highlight limitations such as limited follow-up duration in some studies.


Q: Is it safe to drink alcohol in moderation while taking Nacrom?

A: Regulatory patient information advises consulting a healthcare professional to discuss the consumption of alcohol while using this medicine.


Q: Does Nacrom interact with birth control pills?

A: Official drug interaction summaries do not list any known significant systemic interactions between cromolyn sodium and oral contraceptive medications.


Q: How common are serious allergic reactions to Nacrom?

A: Anaphylactic reactions, a severe type of allergic reaction, have been reported rarely in postmarketing data. Official safety data is noted as incomplete, and the complete frequency of serious allergic reactions is therefore not fully available.


Q: Can Nacrom cause mood changes or anxiety?

A: Regulatory-based summaries list psychiatric effects such as anxiety and depression as having been reported in some clinical contexts. However, the observed frequency of these effects is not always defined in the official product labeling.


Q: Is Nacrom safe during pregnancy or while breastfeeding?

A: Pregnancy: The drug is assigned to Pregnancy Category B by the FDA. Regulatory guidance indicates its use is not recommended unless clearly needed. Breastfeeding: It is not definitively known if the medicine is excreted into human milk, but due to its poor absorption, experts generally consider its use acceptable.


Q: What is the recommended way to stop taking Nacrom?

A: Official warnings state that caution should be used when withdrawing the drug or tapering the dose. Stopping abruptly may lead to a reoccurrence or worsening of symptoms of the condition being treated.


Q: Do studies show Nacrom is effective for all types of [Treated condition]?

A: Research has focused on specific manifestations, such as seasonal and perennial rhinitis, and for the prophylactic use in mild-to-moderate asthma. The research does not apply to the management of acute or severe asthma episodes.


Q: Are there certain groups of people who should not use Nacrom?

A: Official warnings state that the medicine is contraindicated for patients with a known hypersensitivity (allergic reaction) to cromolyn sodium. Caution and dose adjustment may also be necessary for systemic forms in patients with impaired renal or hepatic function.


Q: How long does the effect of one dose of Nacrom last?

A: The drug's mechanism is prophylactic, meaning it must be present continuously to prevent symptoms. Its therapeutic effect is linked to the recommended administration schedule, which is up to six times per day, with doses spaced approximately every four to six hours.


Q: Can I crush or chew Nacrom tablets?

A: The nasal solution formulation is a spray and is not intended to be crushed, chewed, or swallowed. Any non-nasal forms, such as oral capsules, have specific instructions for their preparation and administration that must be followed exactly.


Q: What is the purpose of the black box warning (if any) on Nacrom?

A: Cromolyn sodium, which is classified as a mast cell stabilizer, does not carry a Black Box Warning on the package labeling. This type of warning is typically reserved for drugs with a significantly greater risk of serious side effects.


Q: Does Nacrom affect sleep patterns?

A: Regulatory-based summaries list sleep-related issues such as insomnia (difficulty sleeping) as having been reported in some clinical contexts. However, the observed frequency of this adverse reaction is not always defined in the official product labeling.


Q: Are there any known interactions between Nacrom and herbal remedies?

A: Official patient information advises consulting a healthcare professional about all products, including herbal remedies, as a precaution regarding potential interactions.


Q: Where can I find the official patient information leaflet for Nacrom?

A: Official patient information leaflets and prescribing information can be found in government databases that publish drug labels. These include sources such as the FDA's DailyMed in the United States or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

How should Nacrom be stored and disposed of?

How to Store and Dispose of Nacrom (Cromolyn Sodium)

The official storage conditions for Nacrom are strictly defined to maintain product stability and efficacy. The medication must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), and must be protected from light. It is essential not to freeze the solutions. All forms must be kept out of the sight and reach of children.

Unit-dose packaging, such as vials or ampules, should remain in the original foil pouch or carton until the time of use. The ophthalmic solution must be discarded four weeks after opening. Unused or expired Nacrom must be disposed of according to local laws and regulations for pharmaceutical waste, and must not be placed in household drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nacrom found in:

A-Z Index: